Carotid body hyperplasia and enhanced ventilatory responses to hypoxia in mice with heterozygous deficiency of PHD2

Journal of Physiology

Volumn 591, Issue 14, 2013, Pages 3565-3577

  Bishop, Tammie ^a   Talbot, Nick P ^b   Turner, Philip J ^b   Nicholls, Lynn G ^a   Pascual, Alberto ^c   Hodson, Emma J ^a   Douglas, Gillian ^a   Fielding, James W ^a   Smith, Thomas G ^b   Demetriades, Marina ^b   Schofield, Christopher J ^b   Robbins, Peter A ^b   Pugh, Christopher W ^a   Buckler, Keith J ^b   Ratcliffe, Peter J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROLYL HYDROXYLASE 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAROTID BODY HYPERPLASIA; CELL PROLIFERATION; CELL VOLUME; CONTROLLED STUDY; ENZYME DEFICIENCY; ENZYME INHIBITION; ERYTHROPOIESIS; GENE; GENE FUNCTION; GENE INACTIVATION; HEMATOCRIT; HETEROZYGOTE; HYPERPLASIA; HYPOXIA; MALE; MOUSE; NONHUMAN; OXYGEN SENSING; PHD2 GENE; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; RESPIRATORY DRIVE; RESPIRATORY FUNCTION; RETICULOCYTOSIS;

ANIMALS; ANOXIA; CAROTID BODY; HYPERPLASIA; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR-PROLINE DIOXYGENASES; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PULMONARY VENTILATION;

EID: 84880723562     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2012.247254     Document Type: Article

References (43)

1. Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW, Ratcliffe PJ & Gleadle JM (2004). Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem 279, 38458-38465.
2. Aragones J, Schneider M, Van Geyte K, Fraisl P, Dresselaers T, Mazzone M, Dirkx R, Zacchigna S, Lemieux H, Jeoung NH, Lambrechts D, Bishop T, Lafuste P, Diez-Juan A, Harten SK, Van Noten P, De Bock K, Willam C, Tjwa M, Grosfeld A, Navet R, Moons L, Vandendriessche T, Deroose C, Wijeyekoon B, Nuyts J, Jordan B, Silasi-Mansat R, Lupu F, Dewerchin M, Pugh C, Salmon P, Mortelmans L, Gallez B, Gorus F, Buyse J, Sluse F, Harris RA, Gnaiger E, Hespel P, Van Hecke P, Schuit F, Van Veldhoven P, Ratcliffe P, Baes M, Maxwell P & Carmeliet P (2008). Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet 40, 170-180.
3. Bernhardt WM, Wiesener MS, Scigalla P, Chou J, Schmieder RE, Gunzler V & Eckardt KU (2010). Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol 21, 2151-2156.
4. Berra E, Benizri E, Ginouves A, Volmat V, Roux D & Pouyssegur J (2003). HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1α in normoxia. EMBO J 22, 4082-4090.
5. -/- mice. Mol Cell Biol 28, 3386-3400.
6. Douglas CG, Haldane JS, Henderson Y, Schneider EC, Webb GB & Richards J (1913). Physiological observations made on Pike's Peak, Colorado, with special reference to adaptation to low barometric pressures. Philos Trans R Soc Lond B Biol Sci 203, 185-318.
7. Formenti F, Beer PA, Croft QP, Dorrington KL, Gale DP, Lappin TR, Lucas GS, Maher ER, Maxwell PH, McMullin MF, O'Connor DF, Percy MJ, Pugh CW, Ratcliffe PJ, Smith TG, Talbot NP & Robbins PA (2011). Cardiopulmonary function in two human disorders of the hypoxia-inducible factor (HIF) pathway: von Hippel-Lindau disease and HIF-2α gain-of-function mutation. FASEB J 25, 2001-2011.
8. Fraisl P, Aragones J & Carmeliet P (2009). Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. Nat Rev Drug Discov 8, 139-152.
9. Holmquist-Mengelbier L, Fredlund E, Lofstedt T, Noguera R, Navarro S, Nilsson H, Pietras A, Vallon-Christersson J, Borg A, Gradin K, Poellinger L & Pahlman S (2006). Recruitment of HIF-1α and HIF-2α to common target genes is differentially regulated in neuroblastoma: HIF-2α promotes an aggressive phenotype. Cancer Cell 10, 413-423.
10. Howard LS & Robbins PA (1995). Ventilatory response to 8 h of isocapnic and poikilocapnic hypoxia in humans. J Appl Physiol 78, 1092-1097.
11. Hsieh MM, Linde NS, Wynter A, Metzger M, Wong C, Langsetmo I, Lin A, Smith R, Rodgers GP, Donahue RE, Klaus SJ & Tisdale JF (2007). HIF-prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. Blood 110, 2140-2147.
12. Hu CJ, Wang LY, Chodosh LA, Keith B & Simon MC (2003). Differential roles of hypoxia-inducible factor 1α (HIF-1α) and HIF-2α in hypoxic gene regulation. Mol Cell Biol 23, 9361-9374.
13. Ishiguro T, Iwase M, Kanamaru M, Izumizaki M, Ohshima Y & Homma I (2006). Impaired ventilation and metabolism response to hypoxia in histamine H1 receptor-knockout mice. Respir Physiol Neurobiol 154, 331-341.
14. 2 homeostasis by hypoxia-inducible factor 1α. Genes Dev 12, 149-162.
15. Kaelin WG Jr & Ratcliffe PJ (2008). Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 30, 393-402.
16. Kay JM & Laidler P (1977). Hypoxia and the carotid body. J Clin Pathol Suppl (R Coll Pathol) 11, 30-44.
17. Kline DD, Peng YJ, Manalo DJ, Semenza GL & Prabhakar NR (2002). Defective carotid body function and impaired ventilatory responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1α. Proc Natl Acad Sci U S A 99, 821-826.
18. Kotch LE, Iyer NV, Laughner E & Semenza GL (1999). Defective vascularization of HIF-1α-null embryos is not associated with VEGF deficiency but with mesenchymal cell death. Dev Biol 209, 254-267.
19. Laidler P & Kay JM (1975). A quantitative morphological study of the carotid bodies of rats living at a simulated altitude of 4300 metres. J Pathol 117, 183-191.
20. McGregor KH, Gil J & Lahiri S (1984). A morphometric study of the carotid body in chronically hypoxic rats. J Appl Physiol 57, 1430-1438.
21. Mazzone M, Dettori D, Leite de Oliveira R, Loges S, Schmidt T, Jonckx B, Tian YM, Lanahan AA, Pollard P, Ruiz de Almodovar C, De Smet F, Vinckier S, Aragones J, Debackere K, Luttun A, Wyns S, Jordan B, Pisacane A, Gallez B, Lampugnani MG, Dejana E, Simons M, Ratcliffe P, Maxwell P & Carmeliet P (2009). Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 136, 839-851.
22. Menrad H, Werno C, Schmid T, Copanaki E, Deller T, Dehne N & Brune B (2010). Roles of hypoxia-inducible factor-1α (HIF-1α) versus HIF-2α in the survival of hepatocellular tumor spheroids. Hepatology 51, 2183-2192.
23. Ortega-Saenz P, Pascual A, Piruat JI & Lopez-Barneo J (2007). Mechanisms of acute oxygen sensing by the carotid body: lessons from genetically modified animals. Respir Physiol Neurobiol 157, 140-147.
24. Pan J, Yeger H, Ratcliffe P, Bishop T & Cutz E (2012). Hyperplasia of pulmonary neuroepithelial bodies (NEB) in lungs of prolyl hydroxylase-1(PHD-1) deficient mice. Adv Exp Med Biol 758, 149-155.
25. Pardal R, Ortega-Saenz P, Duran R & Lopez-Barneo J (2007). Glia-like stem cells sustain physiologic neurogenesis in the adult mammalian carotid body. Cell 131, 364-377.
26. Peng J, Zhang L, Drysdale L & Fong GH (2000). The transcription factor EPAS-1/hypoxia-inducible factor 2α plays an important role in vascular remodeling. Proc Natl Acad Sci U S A 97, 8386-8391.
27. Peng YJ, Nanduri J, Khan SA, Yuan G, Wang N, Kinsman B, Vaddi DR, Kumar GK, Garcia JA, Semenza GL & Prabhakar NR (2011). Hypoxia-inducible factor 2α (HIF-2α) heterozygous-null mice exhibit exaggerated carotid body sensitivity to hypoxia, breathing instability, and hypertension. Proc Natl Acad Sci U S A 108, 3065-3070.
28. Peng YJ, Yuan G, Ramakrishnan D, Sharma SD, Bosch-Marce M, Kumar GK, Semenza GL & Prabhakar NR (2006). Heterozygous HIF-1α deficiency impairs carotid body-mediated systemic responses and reactive oxygen species generation in mice exposed to intermittent hypoxia. J Physiol 577, 705-716.
29. Prabhakar NR & Jacono FJ (2005). Cellular and molecular mechanisms associated with carotid body adaptations to chronic hypoxia. High Alt Med Biol 6, 112-120.
30. Prabhakar NR & Semenza GL (2012). Adaptive and maladaptive cardiorespiratory responses to continuous and intermittent hypoxia mediated by hypoxia-inducible factors 1 and 2. Physiol Rev 92, 967-1003.
31. Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL, Pugh CW, Maxwell PH, Harris AL & Ratcliffe PJ (2005). Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25, 5675-5686.
32. Robbins PA (2007). Role of the peripheral chemoreflex in the early stages of ventilatory acclimatization to altitude. Respir Physiol Neurobiol 158, 237-242.
33. Rose NR, McDonough MA, King ON, Kawamura A & Schofield CJ (2011). Inhibition of 2-oxoglutarate dependent oxygenases. Chem Soc Rev 40, 4364-4397.
34. Schley G, Klanke B, Schödel J, Kroning S, Turkoglu G, Beyer A, Hagos Y, Amann K, Burckhardt BC, Burzlaff N, Eckardt KU & Willam C (2012). Selective stabilization of HIF-1α in renal tubular cells by 2-oxoglutarate analogues. Am J Pathol 181, 1595-1606.
35. Schneider M, Van Geyte K, Fraisl P, Kiss J, Aragones J, Mazzone M, Mairbaurl H, De Bock K, Jeoung NH, Mollenhauer M, Georgiadou M, Bishop T, Roncal C, Sutherland A, Jordan B, Gallez B, Weitz J, Harris RA, Maxwell P, Baes M, Ratcliffe P & Carmeliet P (2010). Loss or silencing of the PHD1 prolyl hydroxylase protects livers of mice against ischemia/reperfusion injury. Gastroenterology 138, 1143-1154 e1141-1142.
36. Schödel J, Oikonomopoulos S, Ragoussis J, Pugh CW, Ratcliffe PJ & Mole DR (2011). High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. Blood 117, e207-217.
37. -/- mice. Nat Genet 35, 331-340.
38. Smith TG, Brooks JT, Balanos GM, Lappin TR, Layton DM, Leedham DL, Liu C, Maxwell PH, McMullin MF, McNamara CJ, Percy MJ, Pugh CW, Ratcliffe PJ, Talbot NP, Treacy M & Robbins PA (2006). Mutation of von Hippel-Lindau tumour suppressor and human cardiopulmonary physiology. PLoS Med 3, e290.
39. Takeda K, Ho VC, Takeda H, Duan LJ, Nagy A & Fong GH (2006). Placental but not heart defects are associated with elevated hypoxia-inducible factor α levels in mice lacking prolyl hydroxylase domain protein 2. Mol Cell Biol 26, 8336-8346.
40. Tian H, Hammer RE, Matsumoto AM, Russell DW & McKnight SL (1998). The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev 12, 3320-3324.
41. Tian YM, Yeoh KK, Lee MK, Eriksson T, Kessler BM, Kramer HB, Edelmann MJ, Willam C, Pugh CW, Schofield CJ & Ratcliffe PJ (2011). Differential sensitivity of hypoxia inducible factor hydroxylation sites to hypoxia and hydroxylase inhibitors. J Biol Chem 286, 13041-13051.
42. Wang Z, Schley G, Turkoglu G, Burzlaff N, Amann KU, Willam C, Eckardt KU & Bernhardt WM (2012). The protective effect of prolyl-hydroxylase inhibition against renal ischaemia requires application prior to ischaemia but is superior to EPO treatment. Nephrol Dial Transplant 27, 929-936.
43. Yan L, Colandrea VJ & Hale JJ (2010). Prolyl hydroxylase domain-containing protein inhibitors as stabilizers of hypoxia-inducible factor: small molecule-based therapeutics for anemia. Expert Opin Ther Pat 20, 1219-1245.